New hope for hard-to-treat colon cancer: drug combo tested in clinical trial
NCT ID NCT07261709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial compares a new drug combination (trifluridine/tipiracil plus fruquintinib) against a standard one (trifluridine/tipiracil plus bevacizumab) in 236 people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if the new combo works as well or better at controlling the cancer and improving survival. Participants take oral pills and receive intravenous infusions over several weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trifluridine/tipiracil plus fruquintinib
- What this could lead to
- If this works, it could offer a new treatment option for people with advanced colorectal cancer who have run out of standard therapies.
- What could go wrong
- This is an early phase 2 trial with only 236 participants, so results may not apply to everyone. The new combo might not be as effective or safe as the current standard.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for Tough-to-Treat colorectal cancer: drug targets specific protein
- Virus therapy fails to advance in colorectal cancer trial
- New hope for Tough-to-Treat colorectal cancer: experimental combo enters Late-Stage trial
- New combo targets liver tumors in hard-to-treat colorectal cancer
- New combo therapy offers hope for hard-to-treat GI cancers